Villela L, Herrera-Urbina O, Martínez-Flores P, González C

Language: Spanish
References: 15
Page: 1-4
PDF size: 278.99 Kb.

Text Extraction

No abstract.

REFERENCES

1. Rivera Franco MM, Leon Rodriguez E, Gomez Martin D, et al. Comparison of T cell subsets and cytokines between steady-state and G-CSF-primed bone marrow and its association with graft-versus-host-disease. Blood 2017; Poster # 4505 ASH meeting.

2. Colunga Pedraza PR, Gomez de Leon A, Sotomayor Duque G, et al. Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide is feasible. Experience in a single Latin-American center. Blood 2017; Poster # 1940 ASH meeting.

3. Ruiz-Argüelles GJ, Olivares Gazca JC, Murrieta-Alvarez I, et al. Modifications to the “classical” autologous hematopoietic stem cell transplantation in multiple sclerosis: efficacy and safety study of a less toxic approach which improves the neurological condition. A Mexican perspective. Blood 2017; Poster # 3290 ASH meeting.

4. Garcia-Horton A, Carballo-Zarate A, Palma-Berre L, et al. Distribution of lymphomas in Mexico: A descriptive study. Blood 2017; Poster # 2127 ASH meeting.

5. Martinez Murillo C, Montaño Figueroa E, Castellanos Sinco HB, MD, et al. Tissue factor expression as a prognostic marker in patients with B-cell malignant lymphoma. Blood 2017; Poster # 3700 ASH meeting.

6. Myrna Candelaria, Derlis Emilio Gonzalez, Surender Kumar Beniwal, et al. A randomized, double-blind, phase III study comparing proposed biosimilar rituximab (RTXM83) versus reference rituximab, both in combination with CHOP, in the first line treatment of patients with diffuse large B-cell lymphoma (DLBCL). Blood 2017; Poster #1556 ASH meeting.

7. Hungria VTM, Martinez-Banos DM, Ramos Penafiel C, Miguel CE, Vela-Ojeda J. Treatment patterns and survival outcomes in Latin American patients with newly diagnosed multiple myeloma: A retrospective medical chart review study, 2008-2016. Blood 2017; Poster # 2113 ASH meeting.

8. Lentzsch S, Quach H, Chanan-Khan AA, Horvath N, Capra M, Ovilla R, MD et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone for relapsed/refractory multiple myeloma (RRMM) patients: an update of overall survival in castor. Blood 2017; Poster # 1852 ASH meeting.

9. Gonzalez-Montalvo P, Romo H, Vega-Vega L, et al. Collaborative risk-adapted treatment for pediatric acute lymphoblastic leukemia in Mexico. Blood 2017; Poster #2116 ASH meeting.

10. Ramos Penafiel CO, Olarte Carrillo I, Cerón Maldonado R, et al. Effect of metformin in patients with ALL who express high levels of the ABCB1 gene and its impact on survival. Blood 2017; Poster # 3885 ASH meeting.

11. Guerrero Gómez KN, Gonzalez-Ramella O, Friedrich P. Primary caregiver’s knowledge related to cancer: Opportune detection and prevention of treatment complications in a pediatric Hematology-Oncology Unit. Blood 2017; Poster # 4700 ASH meeting.

12. Cabrera Coarcia A, Vargas-Trujillo S, Hernández-Company A, MD, et al. A Multicenter retrospective experience of hematologic neoplasms in pregnancy. Blood 2017; Poster # 4716 ASH meeting.

13. Kuter DJ, Newland A, Chong BH, Rodeghiero F, Tejeda Romero M, et al. Comparison of the effects of the thrombopoietin (TPO) receptor agonist romiplostim in patients with immune thrombocytopenia (ITP) for ≤ 1 Year vs. > 1 year. Blood 2017; Poster # 1055 ASH meeting.

14. Rajme S, Vargas-Serafin C, Demichelis R, Bourlon C. Role of bone marrow aspirate and biopsy in the diagnosis of hiv patients presenting with low blood counts. Blood 2017; Poster # 1016 ASH meeting.

15. Devos T, Matteo Pica G, Zerazhi H, et al. Safety and efficacy of Ruxolitinib (rux) in an open-label, multicenter, expanded treatment protocol in patients (Pts) with polycythemia vera (PV) who are hydroxyurea (HU) resistant or intolerant and for whom no alternative treatments are available. Blood 2017; Poster # 2918 ASH meeting.